33.下列有關固體基質－抗體－抗原（solid matrix-antibody-antigen, SMAA）複合物疫苗之敘述，何者錯誤？
(A)屬於多價性疫苗，具有B細胞及T細胞抗原決定位
(B)可誘發強烈的體液性及細胞媒介性免疫反應
(C)可增強吞噬細胞的吞噬作用而提高免疫力
(D)乃是利用界面活性劑將蛋白質抗原嵌合成蛋白質微胞

SMAA複合物是多價次單位疫苗，藉由結合...

Fig. 1. Methods used to construct SMAA complexes to form multivalent immunogens. (a) Different mAbs are attached to independent solid matrices prior to the binding of antigens. The resulting SMAA complexes are mixed together before they are used as immunogens. (b) Different mAbs are attached to the same solid matrix prior to the formation of the SMAA complexes. (c)A single mAb that recognizes a target antigen, which may be attached to different microbial antigens, is used in the construction of SMAA complexes (see text). (d) The same method as panel(b) except that additional mAbs (for example to host ceil surface antigens) and proteins (for example cholera toxin) are also attached to the solid matrix specifically to enhance particular types of immune responses.

Immunology Today, Vol. 10, No. 10, 1989